Table 6

Prior cancer therapy of the two patients with NSCLC previously treated with anti-PD-1/PD-L1 agents who responded after treatment with enoblituzumab+pembrolizumab

Patient #Prior regimenLine of therapyDuration of treatment
(first to last dose)
Number of cycles administeredBest responseReason for discontinuation
Carboplatin/Gemcitabine1L120 days
(=4 months)
6Progressive diseaseProgression/Recurrence
GemcitabineMaintenance33 days
(=1 month, 2 days)
1Progressive diseaseProgression/Recurrence
Carboplatin/Pemetrexed2L92 days
(=3 months, 3 days)
4Progressive diseaseProgression/Recurrence
Nivolumab3L570 days
(=1 year, 10 months)
40Stable diseaseProgression/Recurrence
Carboplatin/Paclitaxel1L50 days
(=1 month, 22 days)
2Stable diseaseProgression/Recurrence
Atezolizumab2L64 days
(=2 months, 3 days)
4Progressive diseaseProgression/Recurrence
  • CPI, checkpoint inhibitor; 1L, first line; 2L, second line; 3L, third line; NSCLC, non–small cell lung cancer; PD-1, programmed cell death-1; PD-L1, programmed death-ligand 1.